{"filing":{"accession_number":"0001193125-26-354053","cik":"0001774857","ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-14","primary_document":"ck0001774857-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526354053/ck0001774857-20260814.htm"},"events":[{"id":28253,"run_id":25834,"accession_number":"0001193125-26-354053","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Aardvark Therapeutics' 2026 Annual Meeting of Stockholders held on August 14, 2026. The filing presents voting outcomes for three proposals: election of two Class I directors (Victor Tong, Jr. and Jeffrey Chi, Ph.D.), ratification of BDO USA, P.C. as independent auditor, and approval of stock option repricing under three equity plans. All three proposals passed. This is material as shareholder votes on director elections, auditor ratification, and equity compensation arrangements directly affect investor assessment of governance and capital structure.","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30135,"accession_number":"0001193125-26-354053","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Aardvark Therapeutics' 2026 Annual Meeting of Stockholders held on August 14, 2026. The filing presents voting outcomes for three proposals: election of two Class I directors (Victor Tong, Jr. and Jeffrey Chi, Ph.D.), ratification of BDO USA, P.C. as independent auditor, and approval of stock option repricing under three equity plans. All three proposals passed. This is material as shareholder votes on director elections, auditor ratification, and equity compensation arrangements directly affect investor assessment of governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:11:43.402671+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30135,"accession_number":"0001193125-26-354053","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Aardvark Therapeutics' 2026 Annual Meeting of Stockholders held on August 14, 2026. The filing presents voting outcomes for three proposals: election of two Class I directors (Victor Tong, Jr. and Jeffrey Chi, Ph.D.), ratification of BDO USA, P.C. as independent auditor, and approval of stock option repricing under three equity plans. All three proposals passed. This is material as shareholder votes on director elections, auditor ratification, and equity compensation arrangements directly affect investor assessment of governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:11:43.402671+00:00","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-08-17"}]}